Literature DB >> 26032414

Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics.

Yijing Yu1, Ioannis Prassas2, Apostolos Dimitromanolakis2, Eleftherios P Diamandis3.   

Abstract

Kallikrein-related peptidases (KLKs) are a group of serine proteases widely expressed in various tissues and involved in a wide range of physiological and pathological processes. Although our understanding of the pathophysiological roles of most KLKs has blossomed in recent years, identification of the direct endogenous substrates of human KLKs remains an unmet objective. In this study we employed a degradomics approach to systemically investigate the endogenous substrates of KLK7 in an effort to understand the molecular pathways underlying KLK7 action in skin. We identified several previously known as well as novel protein substrates. Our most promising candidates were further validated with the use of targeted quantitative proteomics (selected reaction monitoring methods) and in vitro recombinant protein digestion assays. Our study revealed midkine, CYR61, and tenascin-C as endogenous substrates for KLK7. Interestingly, some of these substrates (e.g. midkine) were prone to proteolytic cleavage only by KLK7 (and not by other skin-associated KLKs), whereas others (e.g. CYR61 and tenascin-C) could be digested by several KLKs. Furthermore, using melanoma cell line, we show that KLK7-mediated cleavage of midkine results in an overall reduction in the pro-proliferative and pro-migratory effect of midkine. An inverse relation between KLK7 and midkine is also observed in human melanoma tissues. In summary, our degradomics approach revealed three novel endogenous substrates for KLK7, which may shed more light on the pathobiological roles of KLK7 in human skin. Similar substrate screening approaches could be applied for the discovery of biological substrates of other protease.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  degradomics; kallikrein; protease; proteolysis; proteomics; substrate specificity

Mesh:

Substances:

Year:  2015        PMID: 26032414      PMCID: PMC4505025          DOI: 10.1074/jbc.M115.643551

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Midkine and pleiotrophin have bactericidal properties: preserved antibacterial activity in a family of heparin-binding growth factors during evolution.

Authors:  Sara L Svensson; Mukesh Pasupuleti; Björn Walse; Martin Malmsten; Matthias Mörgelin; Camilla Sjögren; Anders I Olin; Mattias Collin; Artur Schmidtchen; Ruth Palmer; Arne Egesten
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

2.  Distribution of 15 human kallikreins in tissues and biological fluids.

Authors:  Julie L V Shaw; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2007-06-15       Impact factor: 8.327

3.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

Review 4.  Klk8, a multifunctional protease in the brain and skin: analysis of knockout mice.

Authors:  Shigetaka Yoshida
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

5.  Cell adhesion and communication proteins are differentially expressed in melanoma progression model.

Authors:  Gisele Gargantini Rezze; José Humberto Tavares Guerreiro Fregnani; João Duprat; Gilles Landman
Journal:  Hum Pathol       Date:  2010-12-28       Impact factor: 3.466

6.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

7.  Solution structure of midkine, a new heparin-binding growth factor.

Authors:  W Iwasaki; K Nagata; H Hatanaka; T Inui; T Kimura; T Muramatsu; K Yoshida; M Tasumi; F Inagaki
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

8.  Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.

Authors:  Azza Eissa; Vanessa Amodeo; Christopher R Smith; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

Review 9.  Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions.

Authors:  Azza Eissa; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

Review 10.  Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics.

Authors:  David Rodríguez; Charlotte J Morrison; Christopher M Overall
Journal:  Biochim Biophys Acta       Date:  2009-10-01
View more
  11 in total

Review 1.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

2.  Proteomic Findings in Melanoma.

Authors:  Deepanwita Sengupta; Alan J Tackett
Journal:  J Proteomics Bioinform       Date:  2016-04-27

3.  Matrix Metalloproteinase 10 Degradomics in Keratinocytes and Epidermal Tissue Identifies Bioactive Substrates With Pleiotropic Functions.

Authors:  Pascal Schlage; Tobias Kockmann; Fabio Sabino; Jayachandran N Kizhakkedathu; Ulrich Auf dem Keller
Journal:  Mol Cell Proteomics       Date:  2015-10-16       Impact factor: 5.911

Review 4.  The past, present, and future of enzyme-based therapies.

Authors:  Jennifer N Hennigan; Michael D Lynch
Journal:  Drug Discov Today       Date:  2021-09-16       Impact factor: 7.851

5.  Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.

Authors:  Lakmali Munasinghage Silva; Thomas Kryza; Thomas Stoll; Christine Hoogland; Ying Dong; Carson Ryan Stephens; Marcus Lachlan Hastie; Viktor Magdolen; Oded Kleifeld; Jeffrey John Gorman; Judith Ann Clements
Journal:  Mol Cell Proteomics       Date:  2019-01-31       Impact factor: 5.911

Review 6.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

7.  Ablation of kallikrein 7 (KLK7) in adipose tissue ameliorates metabolic consequences of high fat diet-induced obesity by counteracting adipose tissue inflammation in vivo.

Authors:  Konstanze Zieger; Juliane Weiner; Anne Kunath; Martin Gericke; Kerstin Krause; Matthias Kern; Michael Stumvoll; Nora Klöting; Matthias Blüher; John T Heiker
Journal:  Cell Mol Life Sci       Date:  2017-09-20       Impact factor: 9.261

8.  Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.

Authors:  Kiwami Kidana; Takuya Tatebe; Kaori Ito; Norikazu Hara; Akiyoshi Kakita; Takashi Saito; Sho Takatori; Yasuyoshi Ouchi; Takeshi Ikeuchi; Mitsuhiro Makino; Takaomi C Saido; Masahiro Akishita; Takeshi Iwatsubo; Yukiko Hori; Taisuke Tomita
Journal:  EMBO Mol Med       Date:  2018-03       Impact factor: 12.137

9.  Thrombin alters the synthesis and processing of CYR61/CCN1 in human corneal stromal fibroblasts and myofibroblasts through multiple distinct mechanisms.

Authors:  Emily A Andreae; Debra J Warejcka; Sally S Twining
Journal:  Mol Vis       Date:  2020-07-29       Impact factor: 2.367

10.  An unexpected switch in peptide binding mode: from simulation to substrate specificity.

Authors:  Ursula Kahler; Julian E Fuchs; Peter Goettig; Klaus R Liedl
Journal:  J Biomol Struct Dyn       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.